Cowen reissued their hold rating on shares of Qiagen (NASDAQ:QGEN) in a research report report published on Thursday, December 21st. Cowen currently has a $34.00 target price on the stock.
A number of other equities research analysts also recently commented on QGEN. DZ Bank reaffirmed a neutral rating on shares of Qiagen in a research report on Monday, August 28th. Zacks Investment Research raised shares of Qiagen from a hold rating to a buy rating and set a $39.00 price objective for the company in a research report on Tuesday, October 10th. Commerzbank restated a buy rating on shares of Qiagen in a research note on Tuesday, November 7th. JPMorgan Chase & Co. restated a neutral rating on shares of Qiagen in a research note on Tuesday, November 7th. Finally, Deutsche Bank restated a buy rating on shares of Qiagen in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. Qiagen presently has an average rating of Hold and an average target price of $34.63.
Qiagen (QGEN) opened at $32.65 on Thursday. Qiagen has a 1-year low of $27.51 and a 1-year high of $36.34. The stock has a market cap of $7,540.00, a P/E ratio of 83.72, a PEG ratio of 1.80 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68.
Qiagen (NASDAQ:QGEN) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. The company had revenue of $364.00 million during the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. sell-side analysts predict that Qiagen will post 1.25 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Acrospire Investment Management LLC grew its holdings in Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after purchasing an additional 349 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in Qiagen by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after acquiring an additional 20 shares in the last quarter. Quadrant Capital Group LLC grew its stake in Qiagen by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after acquiring an additional 225 shares in the last quarter. Koch Industries Inc. bought a new position in Qiagen in the 2nd quarter worth about $231,000. Finally, Hartford Investment Management Co. bought a new position in Qiagen in the 3rd quarter worth about $231,000. Institutional investors own 62.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cowen Reaffirms Hold Rating for Qiagen (QGEN)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/14/qiagens-qgen-hold-rating-reaffirmed-at-cowen.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.